RESUMO
The first confirmed case of novel Coronavirus Disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of November 24, 2020, close to 12.2 million cases of COVID-19 was confirmed in the US, with over 255,958 deaths. The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), its unusual and divergent presentation has strengthened the status of COVID-19 as a major public health threat. In this review, we aim to 1- discuss the epidemiological data from various COVID-19 patient cohorts around the world and the USA as well the associated risk factors; 2- summarize the pathophysiology of SARS-CoV-2 infection and the underlying molecular mechanisms for the respiratory and cardiovascular manifestations; 3- highlight the potential treatments and vaccines as well as current clinical trials for COVID-19.
Assuntos
COVID-19/complicações , Doenças Cardiovasculares/tratamento farmacológico , Pneumopatias/tratamento farmacológico , SARS-CoV-2/isolamento & purificação , COVID-19/transmissão , COVID-19/virologia , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/fisiopatologia , Doenças Cardiovasculares/virologia , Gerenciamento Clínico , Saúde Global , Humanos , Pneumopatias/epidemiologia , Pneumopatias/fisiopatologia , Pneumopatias/virologia , Estados Unidos/epidemiologiaRESUMO
The virus responsible for the COVID-19 pandemic continues to pose unmatched challenges in the world. It can cause systemic inflammation, which can lead to multiorgan involvement and subsequent damage. The relationship that possibly exists between the COVID-19 infection, the newly developed vaccines, and thyroid disease are still under extensive investigation. We are reporting the first case of new-onset graves' disease in a young, healthy man after COVID-19 infection and receiving a COVID-19 vaccine dose.